MeCure Industries Plc has released its unaudited financial results for the second quarter ended June 30, 2025, reporting a pre-tax profit of N3.093 billion, representing an impressive 634% year-on-year (YoY) growth compared to Q2 2024.
This strong second-quarter performance pushed H1 2025 pre-tax profit to N3.903 billion, marking a 192% YoY increase and already 18% higher than the company’s full-year 2024 pre-tax profit.
A closer look at the financials shows that the impressive bottom-line growth in Q2 was largely driven by a sharp increase in revenue:
Another contributing factor to the strong profit was the slower growth in the cost of sales relative to revenue:
Despite higher overheads in Q2 2025, the company showed better cost discipline:
As of the close of trading on August 6, 2025, MeCure’s stock was priced at N15.85, reflecting a 14% year-to-date gain.
MeCure Industries’ Q2 2025 performance marks a significant turnaround — driven by booming sales in acute and OTC segments, improved cost efficiency, and stronger gross and operating margins.
The company’s aggressive expansion, largely funded by debt, has heightened its leverage risk.
However, it is generating sufficient operating profit to service this debt, as reflected in the improved interest coverage ratio of 2.49x.